Profound Medical Corp
$ 6.48
-2.85%
02 Jun - close price
- Market Cap 242,372,000 USD
- Current Price $ 6.48
- High / Low $ 6.61 / 6.32
- Stock P/E N/A
- Book Value 1.83
- EPS -1.24
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE -0.71 %
- 52 Week High 8.95
- 52 Week Low 3.76
About
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Analyst Target Price
$11.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-13 | 2025-08-14 | 2025-05-08 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-02 | 2023-08-09 |
| Reported EPS | -0.19 | -0.27 | -0.26 | -0.52 | -0.36 | -0.2 | -0.38 | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 |
| Estimated EPS | -0.25 | -0.302 | -0.38 | -0.4 | -0.28 | -0.3225 | -0.3 | -0.28 | -0.31 | -0.32 | -0.32 | -0.34 |
| Surprise | 0.06 | 0.032 | 0.12 | -0.12 | -0.08 | 0.1225 | -0.08 | 0 | 0.05 | -0.1 | 0.06 | -0.01 |
| Surprise Percentage | 24% | 10.596% | 31.5789% | -30% | -28.5714% | 37.9845% | -26.6667% | 0% | 16.129% | -31.25% | 18.75% | -2.9412% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PROF
2026-05-27 02:39:08
Profound Medical (TSX:PRN) is projected to achieve profitability within the next three years, with analysts forecasting significant growth in earnings and revenue. The company's TULSA-PRO system has shown promising results in clinical trials for prostate cancer and benign prostatic hyperplasia (BPH) treatment, with recent FDA clearances for AI modules and improved reimbursement codes. Insider transactions also indicate confidence in the company, despite past share price declines and profitability challenges.
2026-05-27 02:09:20
Profound Medical Corp. (TSX:PRN) is a commercial-stage medical device company specializing in AI-powered, MRI-guided therapeutic systems for treating diseased tissue. The company's flagship TULSA-PRO system, used for prostate cancer and BPH, recently demonstrated superior functional outcomes compared to robotic radical prostatectomy in its CAPTAIN trial, including better preservation of erectile function and urinary continence. Despite recent positive news like exceeding Q1 2026 earnings estimates and increased Medicare reimbursement for TULSA procedures, the company faces risks such as past shareholder dilution and historical unprofitability, though it is forecast to break even by 2028.
2026-05-20 10:35:22
Profound Medical Corp. (NASDAQ: PROF) has announced an SEC Filing for Form EFFECT, indicating the effectiveness of its S-3 Shelf Registration Statement as of May 19, 2026, at 4:30 P.M. The filing shows a neutral impact and sentiment according to Rhea-AI. Profound Medical Corp. has a market cap of $250.37 million and is ranked #4372 by market capitalization.
2026-05-17 10:11:09
Profound Medical Corp. shareholders re-elected their existing board of directors with strong majorities and reappointed PricewaterhouseCoopers LLP as auditors. However, a significant 36% opposition was noted for the approval of unallocated restricted and deferred share units under the long-term incentive plan, signaling investor concern over equity-based compensation practices. Despite weak financial performance, analysts rate the stock as a "Buy" with a C$12.00 price target, and technical indicators show modest, neutral-to-positive momentum.
2026-05-15 23:40:41
Profound Medical Corp. announced the voting results from its Annual General and Special Meeting of Shareholders, where all eight director nominees were elected and the appointment of PricewaterhouseCoopers LLP as auditor was approved. Shareholders also approved unallocated restricted share units and deferred share units under the company's long-term incentive plan. The company provided an overview of its commercial-stage medical devices, TULSA-PRO® and Sonalleve®, which are used for incision-free ablation therapies.
2026-05-15 20:09:33
Profound Medical Corp. (NASDAQ: PROF) shareholders approved the election of eight directors, the reappointment of PricewaterhouseCoopers LLP as auditors with 99.497% support, and confirmed all unallocated restricted and deferred share units under its long-term incentive plan. The approval for the long-term incentive plan units, which allows for continued grants until May 13, 2029, passed with 63.922% support. This detailed report also outlines the company's executive compensation policies, corporate governance practices, and director compensation.
